FDMT Stock Forecast & Price Target

4D Molecular Therapeutics is supported by a compelling wet AMD thesis centered on 4D-150, a single-dose intravitreal gene therapy that could shift treatment from chronic anti-VEGF injections to durable backbone disease control. Phase 2b PRISM data showed 78% overall treatment burden reduction, 87% reduction in recently diagnosed patients, maintained BCVA and CST control, and no new intraocular inflammation after the 20-week steroid taper, while 2-year follow-up still showed strong durability. The ongoing Phase 3 4FRONT-1 and 4FRONT-2 programs, both designed around Week 52 BCVA non-inferiority, appear de-risked by these safety and efficacy signals, enrollment completion in 4FRONT-2 approximately 4 months ahead of projections, and a path to broader adoption if approved.

4D Molecular Therapeutics is viewed negatively because its lead programs still face meaningful clinical, regulatory, and competitive uncertainty, and the gene therapy field is described as very crowded with programs still early in development. The company’s 4FRONT study could be affected by the same vision-imbalance issues seen in EYPT’s Duravyu, while 4D-150’s expected advantage over Vabysmo and Eylea HD appears limited to a reduction of only about 1 annual injection on average, which may not be compelling enough to drive adoption. It also likely needs additional capital, and the elderly patient base raises reimbursement concerns for a therapy framed around a roughly 5 year benefit horizon.